1. Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma
- Author
-
Yunzhen Ge, Shanzong Wang, Zhen Tan, Weijuan Wang, Xiaoguang Han, and Youli Wang
- Subjects
Male ,Carcinoma, Hepatocellular ,Biochemistry ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Cell Line, Tumor ,Biomarkers, Tumor ,medicine ,Humans ,Diagnostic biomarker ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,business.industry ,Tumor Suppressor Proteins ,Liver Neoplasms ,Membrane Proteins ,Cancer ,General Medicine ,Precancerous lesion ,Middle Aged ,medicine.disease ,Phenotype ,digestive system diseases ,MicroRNAs ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Cancer research ,Suppressor ,Female ,Target gene ,Candidate Disease Gene ,business - Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. miR-484 is previously reported to be a crucial modulator during the process from precancerous lesion to cancer. Tumour suppressor candidate 5 (TUSC5) is a potential tumour suppressor, but its expression and function in HCC are obscure. In this study, we aimed to explore the roles of miR-484 and TUSC5 in HCC, and clarify the relationship between them. We demonstrated that miR-484 was significantly up-regulated in HCC, while TUSC5 was down-regulated. TUSC5 was validated as the target gene of miR-484 and both of them were associated with the prognosis of HCC patients. miR-484 mimics markedly promoted the malignant phenotypes while TUSC5 plasmid had the opposite effect. In conclusion, miR-484/TUSC5 is potential diagnostic biomarkers and therapy targets for HCC.
- Published
- 2019